The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis

N. Kiria (Tbilisi, Georgia), Z. Avaliani (Tbilisi, Georgia), N. Bolokadze (Tbilisi, Georgia), N. Kiria (Tbilisi, Georgia), L. Mikiashvili (Tbilisi, Georgia)

Source: International Congress 2019 – Tuberculosis: treatment and management
Session: Tuberculosis: treatment and management
Session type: Poster Discussion
Number: 5279
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Kiria (Tbilisi, Georgia), Z. Avaliani (Tbilisi, Georgia), N. Bolokadze (Tbilisi, Georgia), N. Kiria (Tbilisi, Georgia), L. Mikiashvili (Tbilisi, Georgia). The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis. 5279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021


Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis
Source: International Congress 2018 – Tuberculosis comorbidities
Year: 2018

Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019


Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020



Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018


Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020


Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Transthyretin in patients with pulmonary tuberculosis co-infected HIV.
Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis
Year: 2021


Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008


The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen
Source: Eur Respir J 2003; 21: 785-788
Year: 2003



The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005

Clinical-evolutive aspects of pulmonary tuberculosis at patients with chronic hepatitis
Source: Annual Congress 2007 - Tuberculosis
Year: 2007


Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection
Source: ISSN=ISSN 1810-6838, ISBN=, page=190
Year: 2006

The clinical flow and efficiency of treatment of pulmonary tuberculosis in patients with chorine organic pasticides and viral hepatitis ‘B‘ markers
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004

Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Year: 2019



Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018

Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 566s
Year: 2002

Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001

Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007


TB in the immunocompromised host
Source: Eur Respir Mon 2012; 58: 230-241
Year: 2012